Format

Send to

Choose Destination
Int J Colorectal Dis. 2020 Feb;35(2):355-359. doi: 10.1007/s00384-019-03476-y. Epub 2019 Dec 17.

Elderly-onset Crohn's disease remarkably responsive to ustekinumab: a case report.

Author information

1
Department of Internal Medicine Division of Gastroenterology and Hepatology, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. maho_9245@yahoo.co.jp.
2
Division of Research Planning and Development, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
3
Department of Internal Medicine Division of Gastroenterology and Hepatology, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.

Abstract

BACKGROUND:

Crohn's disease is intractable and is frequently diagnosed in younger people. No clear policies exist regarding medical treatment for seniors with this disease, and its diagnosis and treatment are often hindered by difficulties attributable to comorbidities, complex differential diagnoses, and polypharmacy. We describe an elderly-onset Crohn's disease patient showing a marked remission-maintaining effect with no adverse events after administration of ustekinumab.

METHODS AND RESULTS:

A 75-year-old patient with Crohn's disease and a history of pulmonary tuberculosis had first presented to our hospital at age 64 years and was hospitalized. Based on physical examinations, colonoscopy, and blood test results, Crohn's disease was diagnosed. The patient experienced secondary losses of responsiveness to two tumor necrosis factor (TNF)-alpha inhibitors, and after repeated hospital admissions, she was administered ustekinumab. The patient's symptoms, endoscopic findings, Crohn's Disease Activity Index, serum albumin, and physical activity levels improved markedly, and disease remission has been maintained for 2 years to date.

CONCLUSION:

Ustekinumab is an effective treatment option for elderly patients with intractable Crohn's disease when TNF-alpha inhibitors are ineffective.

KEYWORDS:

Biologic agents; Crohn’s disease; Elderly patients; Ustekinumab

PMID:
31848740
DOI:
10.1007/s00384-019-03476-y

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center